Visual Abstract

Our aim was to assess differences in glycemic metrics according to diabetes type and therapy in Japan. An optional survey was conducted for users of FreeStyle LibreTM readers in Japan (Jun2020 - Oct2020). Survey responses were linked to glucose data from Jan2017 - Oct2020. Four groups (adults) were used: type 1 diabetes (T1), type 2 on intensive insulin (T2 MDI), T2 on basal or pre-mixed insulin (T2 non-MDI), and T2 not on insulin (T2 non-insulin). A total of 2,434 users in Japan were analyzed: 1,237 T1, 429 T2 MDI, 256 T2 non-MDI, and 512 T2 non-insulin. Glucose control for T2 MDI and T2 non-MDI groups was similar. Mean avg glucose for T1 was similar to T2 insulin users, but TIR was lower and TB70 was higher for T1. The non-insulin group had high engagement (mean 21 scans/day), but tested BG less than once/day prior to the sensor. These patients also largely pay for the device without reimbursement and have more recent diabetes diagnoses than other groups. These data show the variety of users of the FreeStyle Libre system in Japan. The non-insulin group's engagement through high average scan rates despite lack of consistent BG testing before using the sensor demonstrates that patients find value in easier monitoring. High scan rates in all groups indicate that scanning is not a barrier to glucose monitoring. The data selects those users who responded to the optional survey but is comparable to the overall glucose control of all users in Japan.

Disclosure

W. Ogawa: Advisory Panel; Self; Abbott Diabetes, Novo Nordisk Pharma Ltd., Research Support; Self; Eli Lilly Japan K. K., Nippon Boehringer Ingelheim Co. Ltd., Takeda Pharmaceutical Co., Speaker's Bureau; Self; Dainippon Sumitomo Pharm, Kowa Company, Ltd., MSD K. K., Novartis Pharma K. K., Ono Pharmaceutical Co., Ltd. T. Urakami: None. T. Kadowaki: Other Relationship; Self; Asahi Mutual Life Insurance Company, MSD Corporation, Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Pharma Ltd., Takeda Pharmaceutical Company Limited, Research Support; Self; Daiichi Sankyo Company, Limited, Eli Lilly Japan K. K., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD Corporation, Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K. K., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Speaker's Bureau; Self; Astellas Pharma Inc., AstraZeneca, Daiichi Sankyo Company, Limited, Eli Lilly Japan K. K., Kowa Company, Ltd., Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma Corporation, MSD Corporation, Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K. K., Sanwa Kagaku Kenkyusho, Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd. K. Kao: Employee; Self; Abbott Diabetes. L. Brandner: Employee; Self; Abbott Diabetes. K. Shimizu: Employee; Self; Abbott Japan Co., Ltd. T. Dunn: Employee; Self; Abbott Diabetes.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.